457
Participants
Start Date
September 30, 2005
Primary Completion Date
September 30, 2011
Study Completion Date
January 31, 2012
DiaPep277
1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
Placebo
Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
Rudolfstiftung Hospital, Vienna
Donald Gordon Medical Center, Johannesburg
Centre for Diabetes and Endocrinology, Johannesburg
102 Parklands Medical Centre, Durban
Hospital Universitari Arnau de Vilanova, Lleida
Helderberg Clinical Trials Unit, Cape Town
New Groote Schuur Hospital, Cape Town
Laiko hospital, Athens
Hopital La Timone, Marseille
Istituto Clinico Humanitas, Rozzano
CHU de Nîmes/ Hôpital Caremeau, Nîmes
Diabetes Centre for Children and Adolescents, Hanover
Universitätsklinikum, Giessen
Hospital Nuestra Señora de La Candelaria, Santa Cruz de Tenerife
CHU de Grenoble, Grenoble
Schneider Children's Medical Centre, Petah Tikva
Wolfson Medical Centre, Holon
Hopital Edouard Herriot, Lyon
Universita' degli Studi di Bari, Bari
Pohjois-Karjala projektin tutkimussäätiö, Joensuu
Institut für Diabetesforschung an der Klinik und Hochschulambulanz für Kinder- und Jugendmedizin, Munich
Ex Istituto di clinica medica, Palermo
Tutkimusyksikkö Oulu, Oulu
Hadassah University Hospital, Jerusalem
Faculty Hospital, Olomouc
Faculty hospital Motol., Prague
IKEM/Diabetes Centre, Prague
Diabetestutkimus, Vantaa
University Campus Bio-Medico, Rome
"Università La Sapienza", Rome
Hospital de la Santa Creu, Barcelona
Hospital de Sabadell, Sabadell
St. Bartholomew's Hospital, London
Royal Shrewsbury Hospital, Shrewsbury
Lead Sponsor
Andromeda Biotech Ltd.
INDUSTRY